|
|
Left ventricular assist device (LVAD) as destination therapy for patients with endstage heartfailure
“... that left ventricular assist device (LVAD) should be offered to patients only for a limited period of time...”|
|
by Movik, Espen, Hamidi, Vida, Aaserud, Morten, Neilson, Aileen Rae
Published 2008
“... The evidence base regarding the cost-effectiveness of cetuximab is, at the time of writing, weak, particularly...”Published 2008
Norwegian Knowledge Centre for the Health Services
|
|
by Ringerike, Tove, Hamidi, Vida, Hagen, Gunhild, Reikvam, Åsmund
Published 2011
“... that calculated quality-adjusted life years and life time costs. The main findings were that:1. We did not find...”Published 2011
Norwegian Knowledge Centre for the Health Services
|
|
by Movik, Espen, Hamidi, Vida, Natvig Norderhaug, Inger, Klemp, Marianne
Published 2009
“..., with Norwegian cost data associated with the treatment alternatives. Results Mean progression-free time...”Published 2009
Norwegian Knowledge Centre for the Health Services
|
|
by Wisløff, Torbjørn, Hamidi, Vida, Ringerike, Tove, Harboe, Ingrid
Published 2010
Published 2010
Norwegian Knowledge Centre for the Health Services